EMA, the European Medicines Agency warns that repeated vaccine boosters could weaken the immune system
This could illustrate the principle: the dose makes the poison. For example, foxglove, a well-known poison, is used in low doses as a cardiotonic. Similarly, we have the aspirin, Doliprane to name but two, whose overdose is lethal! This applies to all products
All things are poison, and nothing is without poison; only the dose makes something not poisonous.
Paracelsus – philosopher, physician and alchemist of the 16th century
Here is the article from the Bloomberg Agency which is far from being a conspiracy and anti-vax office:
European Union regulators warned that frequent Covid-19 booster shots could adversely affect the immune response and may not be feasible.
Repeat booster doses of the vaccine every four months could eventually weaken the immune response and tire out people, according to the European Medicines Agency. Instead, countries should leave more time between booster programs and tie them to the onset of the cold season in each hemisphere, following the blueprint set out by influenza vaccination strategies, the agency said.
The advice comes as some countries consider the possibility of offering people second booster shots in a bid to provide further protection against surging omicron infections. Earlier this month Israel became the first nation to start administering a second booster, or fourth shot, to those over 60. The U.K. has said that boosters are providing good levels of protection and there is no need for a second shot of the vaccine at the moment, but will review data as it evolves.
Boosters “can be done once, or maybe twice, but it’s not something that we can think should be repeated constantly,” Marco Cavaleri, the EMA head of biological health threats and vaccines strategy, said at a press briefing on Tuesday. “We need to think about how we can transition from the current pandemic setting to a more endemic setting.”
The EU regulator also said at the briefing that oral and intravenous antivirals, such as Paxlovid and Remdesivir, maintain their efficacy against omicron. The agency said that April is the soonest it could approve a new vaccine targeting a specific variant, as the process takes about three to four months. Some of the world’s largest vaccine-makers have said they are looking at producing vaccines that could target new variants.
Source Bloomberg.com here
Photo © Jakub Jirsák
